Kern M A, Schirmacher P
Pathologisches Institut, Universität Heidelberg.
Verh Dtsch Ges Pathol. 2006;90:85-98.
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide and shows increasing incidence. Multimodal strategies against HCC include primary (e.g. immunisation) and secondary (e. g. antiviral therapy) prevention, surgical approaches, novel specific systemic therapies (targeted therapy), and the treatment of comorbidity (cirrhosis). New molecular approaches are currently under development and tackle several specific targets. In this context pathology is needed in many aspects: experimental strategies, development of valid tumor-relevant diagnostic tests as well as morphological evaluation in the context of clinical studies and finally in routine diagnosis.
肝细胞癌(HCC)是全球最常见的恶性肿瘤之一,且发病率呈上升趋势。针对HCC的多模式策略包括一级预防(如免疫接种)和二级预防(如抗病毒治疗)、手术方法、新型特异性全身治疗(靶向治疗)以及合并症(肝硬化)的治疗。目前正在开发新的分子方法并针对多个特定靶点。在这方面,病理学在许多方面都不可或缺:实验策略、有效的肿瘤相关诊断测试的开发、临床研究背景下的形态学评估以及最终的常规诊断。